Pharmacovirological impact of an integrase inhibitor on human immunodeficiency virus type 1 cDNA species in vivo

Journal of Virology

Volumn 83, Issue 15, 2009, Pages 7706-7717

  Goffinet, Christine ^a   Allespach, Ina ^a   Oberbremer, Lena ^a   Golden, Pamela L ^b   Foster, Scott A ^b   Johns, Brian A ^b   Weatherhead, Jason G ^b   Novick, Steven J ^b   Chiswell, Karen E ^b   Garvey, Edward P ^b   Keppler, Oliver T ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; COMPLEMENTARY DNA; EFAVIRENZ; GSK 501015; INTEGRASE INHIBITOR; RALTEGRAVIR; UNCLASSIFIED DRUG; VIRUS DNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENCY; ENZYME INHIBITION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; LONG TERMINAL REPEAT; LYMPHOID ORGAN; MORNING DOSAGE; NONHUMAN; PLASMA PROTEIN BINDING; PRIORITY JOURNAL; RAT; SPLEEN;

ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CELL LINE; DNA, COMPLEMENTARY; DNA, VIRAL; HIV INFECTIONS; HIV INTEGRASE INHIBITORS; HIV-1; HUMANS; PYRONES; PYRROLIDINONES; RATS; RATS, TRANSGENIC; VIRUS INTEGRATION;

ANIMALIA; HUMAN IMMUNODEFICIENCY VIRUS 1; RATTUS;

EID: 67650898933     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.00683-09     Document Type: Article

References (61)

1. Abbott, A. 2004. Laboratory animals: the Renaissance rat. Nature 428:464-466.
2. + T cells even at low inoculums as demonstrated with an improved assay for HIV-1 integration. Virology 368: 60-72.
3. Barbosa, P., P. Charneau, N. Dumey, and F. Clavel. 1994. Kinetic analysis of HIV-1 early replicative steps in a coculture system. AIDS Res. Hum. Retrovir. 10:53-59.
4. Blish, C. A., O. C. Dogan, N. R. Derby, M. A. Nguyen, B. Chohan, B. A. Richardson, and J. Overbaugh. 2008. Human immunodeficiency virus type 1 superinfection occurs despite relatively robust neutralizing antibody responses. J. Virol. 82:12094-12103.
5. Boros, E. E., B. A. Johns, E. P. Garvey, C. S. Koble, and W. H. Miller. 2006. Synthesis and HIV-integrase strand transfer inhibition activity of 7-hydroxy[1,3]thiazolo[5,4-β]pyridin-5(4H)-ones. Bioorg. Med. Chem. Lett. 16:5668-5672.
6. Brussel, A., and P. Sonigo. 2003. Analysis of early human immunodeficiency virus type 1 DNA synthesis by use of a new sensitive assay for quantifying integrated provirus. J. Virol. 77:10119-10124.
7. Butler, S. L., M. S. Hansen, and F. D. Bushman. 2001. A quantitative assay for HIV DNA integration in vivo. Nat. Med. 7:631-634.
8. Butler, S. L., E. P. Johnson, and F. D. Bushman. 2002. Human immunode-ficiency virus cDNA metabolism: notable stability of two-long terminal repeat circles. J. Virol. 76:3739-3747.
9. Cara, A., A. Cereseto, F. Lori, and M. S. Reitz, Jr. 1996. HIV-1 protein expression from synthetic circles of DNA mimicking the extrachromosomal forms of viral DNA. J. Biol. Chem. 271:5393-5397.
10. Daluge, S. M., D. J. Purifoy, P. M. Savina, M. H. St Clair, N. R. Parry, I. K. Dev., P. Novak, K. M. Ayers, J. E. Reardon, G. B. Roberts, et al. 1994. 5-Chloro-2′,3′-dideoxy-3′-fluorouridine (935U83), a selective anti-human immunodeficiency virus agent with an improved metabolic and toxicological profile. Antimicrob. Agents Chemother. 38:1590-1603.
11. Dayam, R., L. Q. Al-Mawsawi, and N. Neamati. 2007. HIV-1 integrase inhibitors: an emerging clinical reality. Drugs R D 8:155-168.
12. DeJesus, E., D. Berger, M. Markowitz, C. Cohen, T. Hawkins, P. Ruane, R. Elion, C. Farthing, L. Zhong, A. K. Cheng, D. McColl, and B. P. Kearney. 2006. Antiviral activity, pharmacokinetics, and dose response of the HIV-1 integrase inhibitor GS-9137 (JTK-303) in treatment-naive and treatmentexperienced patients. J. Acquir. Immune Defic. Syndr. 43:1-5.
13. + T lymphocytes in hu-SCID mice. Proc. Natl. Acad. Sci. USA 100:8927-8932.
14. Garvey, E. P., B. A. Johns, M. J. Gartland, S. A. Foster, W. H. Miller, R. G. Ferris, R. J. Hazen, M. R. Underwood, E. E. Boros, J. B. Thompson, J. G. Weatherhead, C. S. Koble, S. H. Allen, L. T. Schaller, R. G. Sherrill, T. Yoshinaga, M. Kobayashi, C. Wakasa-Morimoto, S. Miki, K. Nakahara, T. Noshi, A. Sato, and T. Fujiwara. 2008. The naphthyridinone GSK364735 is a novel, potent human immunodeficiency virus type 1 integrase inhibitor and antiretroviral. Antimicrob. Agents Chemother. 52:901-908.
15. Ghosn, J., M. L. Chaix, G. Peytavin, E. Rey, J. L. Bresson, C. Goujard, C. Katlama, J. P. Viard, J. M. Treluyer, and C. Rouzioux. 2004. Penetration of enfuvirtide, tenofovir, efavirenz, and protease inhibitors in the genital tract of HIV-1-infected men. AIDS 18:1958-1961.
16. + T lymphocytes: implications for integrase inhibitors. J. Gen. Virol. 86:765-771.
17. Goffinet, C., I. Allespach, and O. T. Keppler. 2007. HIV-susceptible transgenic rats allow rapid preclinical testing of antiviral compounds targeting virus entry or reverse transcription. Proc. Natl. Acad. Sci. USA 104:1015-1020.
18. Goffinet, C., and O. T. Keppler. 2006. Efficient nonviral gene delivery into primary lymphocytes from rats and mice. FASEB J. 20:500-502.
19. Goffinet, C., N. Michel, I. Allespach, H. M. Tervo, V. Hermann, H. G. Krausslich, W. C. Greene, and O. T. Keppler. 2007. Primary T cells from human CD4/CCR5-transgenic rats support all early steps of HIV-1 replication including integration, but display impaired viral gene expression. Retrovirology 4:53.
20. Grinsztejn, B., B. Y. Nguyen, C. Katlama, J. M. Gatell, A. Lazzarin, D. Vittecoq, C. J. Gonzalez, J. Chen, C. M. Harvey, and R. D. Isaacs. 2007. Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial. Lancet 369:1261-1269.
21. Grobler, J. A., K. Stillmock, B. Hu, M. Witmer, P. Felock, A. S. Espeseth, A. Wolfe, M. Egbertson, M. Bourgeois, J. Melamed, J. S. Wai, S. Young, J. Vacca, and D. J. Hazuda. 2002. Diketo acid inhibitor mechanism and HIV-1 integrase: implications for metal binding in the active site of phosphotransferase enzymes. Proc. Natl. Acad. Sci. USA 99:6661-6666.
22. Gulizia, J., M. P. Dempsey, N. Sharova, M. I. Bukrinsky, L. Spitz, D. Goldfarb, and M. Stevenson. 1994. Reduced nuclear import of human immunodeficiency virus type 1 preintegration complexes in the presence of a prototypic nuclear targeting signal. J. Virol. 68:2021-2025.
23. Haggerty, S., and M. Stevenson. 1991. Predominance of distinct viral genotypes in brain and lymph node compartments of HIV-1-infected individuals. Viral Immunol. 4:123-131.
24. Han, Y., M. Wind-Rotolo, H. C. Yang, J. D. Siliciano, and R. F. Siliciano. 2007. Experimental approaches to the study of HIV-1 latency. Nat. Rev. Microbiol. 5:95-106.
25. Hazen, R., R. Harvey, R. Ferris, C. Craig, P. Yates, P. Griffin, J. Miller, I. Kaldor, J. Ray, V. Samano, E. Furfine, A. Spaltenstein, M. Hale, R. Tung, M. St Clair, M. Hanlon, and L. Boone. 2007. In vitro antiviral activity of the novel, tyrosyl-based human immunodeficiency virus (HIV) type 1 protease inhibitor brecanavir (GW640385) in combination with other antiretrovirals and against a panel of protease inhibitor-resistant HIV. Antimicrob. Agents Chemother. 51:3147-3154.
26. Hazuda, D. J., P. Felock, M. Witmer, A. Wolfe, K. Stillmock, J. A. Grobler, A. Espeseth, L. Gabryelski, W. Schleif, C. Blau, and M. D. Miller. 2000. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science 287:646-650.
27. Hazuda, D. J., M. Iwamoto, and L. Wenning. 2009. Emerging pharmacology: inhibitors of human immunodeficiency virus integration. Annu. Rev. Pharmacol. Toxicol. 49:377-394.
28. Huang, L. C., K. C. Clarkin, and G. M. Wahl. 1996. Sensitivity and selectivity of the DNA damage sensor responsible for activating p53-dependent G1 arrest. Proc. Natl. Acad. Sci. USA 93:4827-4832.
29. + T cells by a highly pathogenic simian immunodeficiency virus/HIV type 1 chimera (SHIV): implications for HIV-1 infections of humans. Proc. Natl. Acad. Sci. USA 98:658-663.
30. Jong, A., and S. H. Huang. 2005. Blood-brain barrier drug discovery for central nervous system infections. Curr. Drug Targets Infect. Disord. 5:65-72.
31. Jung, A., R. Maier, J. P. Vartanian, G. Bocharov, V. Jung, U. Fischer, E. Meese, S. Wain-Hobson, and A. Meyerhans. 2002. Multiply infected spleen cells in HIV patients. Nature 418:144.
32. Keppler, O. T., I. Allespach, L. Schuller, D. Fenard, W. C. Greene, and O. T. Fackler. 2005. Rodent cells support key functions of the human immunode-ficiency virus type 1 pathogenicity factor Nef. J. Virol. 79:1655-1665.
33. Keppler, O. T., F. J. Welte, T. A. Ngo, P. S. Chin, K. S. Patton, C. L. Tsou, N. W. Abbey, M. E. Sharkey, R. M. Grant, Y. You, J. D. Scarborough, W. Ellmeier, D. R. Littman, M. Stevenson, I. F. Charo, B. G. Herndier, R. F. Speck, and M. A. Goldsmith. 2002. Progress toward a human CD4/CCR5 transgenic rat model for de novo infection by human immunodeficiency virus type 1. J. Exp. Med. 195:719-736.
34. Keppler, O. T., W. Yonemoto, F. J. Welte, K. S. Patton, D. Iacovides, R. E. Atchison, T. Ngo, D. L. Hirschberg, R. F. Speck, and M. A. Goldsmith. 2001. Susceptibility of rat-derived cells to replication by human immunodeficiency virus type 1. J. Virol. 75:8063-8073.
35. Kim, J., and P. L. Deininger. 1996. Recent amplification of rat ID sequences. J. Mol. Biol. 261:322-327.
36. Kim, J., J. A. Martignetti, M. R. Shen, J. Brosius, and P. Deininger. 1994. Rodent BC1 RNA gene as a master gene for ID element amplification. Proc. Natl. Acad. Sci. USA 91:3607-3611.
37. Konig, R., Y. Zhou, D. Elleder, T. L. Diamond, G. M. Bonamy, J. T. Irelan, C. Y. Chiang, B. P. Tu, P. D. De Jesus, C. E. Lilley, S. Seidel, A. M. Opaluch, J. S. Caldwell, M. D. Weitzman, K. L. Kuhen, S. Bandyopadhyay, T. Ideker, A. P. Orth, L. J. Miraglia, F. D. Bushman, J. A. Young, and S. K. Chanda. 2008. Global analysis of host-pathogen interactions that regulate early-stage HIV-1 replication. Cell 135:49-60.
38. Li, L., J. M. Olvera, K. E. Yoder, R. S. Mitchell, S. L. Butler, M. Lieber, S. L. Martin, and F. D. Bushman. 2001. Role of the non-homologous DNA end joining pathway in the early steps of retroviral infection. EMBO J. 20:3272-3281.
39. Makinson, A., and J. Reynes. 2009. Raltegravir: first integrase inhibitor for the treatment of HIV infection. Future Virol. 4:23-34.
40. Markowitz, M., B. Y. Nguyen, E. Gotuzzo, F. Mendo, W. Ratanasuwan, C. Kovacs, G. Prada, J. O. Morales-Ramirez, C. S. Crumpacker, R. D. Isaacs, L. R. Gilde, H. Wan, M. D. Miller, L. A. Wenning, and H. Teppler. 2007. Rapid and durable antiretroviral effect of the HIV-1 integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study. J. Acquir. Immune Defic. Syndr. 46:125-133.
41. Munch, J., E. Rucker, L. Standker, K. Adermann, C. Goffinet, M. Schindler, S. Wildum, R. Chinnadurai, D. Rajan, A. Specht, G. Gimenez-Gallego, P. C. Sanchez, D. M. Fowler, A. Koulov, J. W. Kelly, W. Mothes, J. C. Grivel, L. Margolis, O. T. Keppler, W. G. Forssmann, and F. Kirchhoff. 2007. Semenderived amyloid fibrils drastically enhance HIV infection. Cell 131:1059-1071.
42. Murray, J. M., S. Emery, A. D. Kelleher, M. Law, J. Chen, D. J. Hazuda, B. Y. Nguyen, H. Teppler, and D. A. Cooper. 2007. Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phase. AIDS 21:2315-2321.
43. Owen, A., B. Chandler, and D. J. Back. 2005. The implications of P-glycoprotein in HIV: friend or foe? Fundam. Clin. Pharmacol. 19:283-296.
44. Pierson, T. C., T. L. Kieffer, C. T. Ruff, C. Buck, S. J. Gange, and R. F. Siliciano. 2002. Intrinsic stability of episomal circles formed during human immunodeficiency virus type 1 replication. J. Virol. 76:4138-4144.
45. Poon, B., and I. S. Chen. 2003. Human immunodeficiency virus type 1 (HIV-1) Vpr enhances expression from unintegrated HIV-1 DNA. J. Virol. 77:3962-3972.
46. Reddy, Y. S., S. S. Min, J. Borland, I. Song, J. Lin, S. Palleja, and W. T. Symonds. 2007. Safety and pharmacokinetics of GSK364735, a human immunodeficiency virus type 1 integrase inhibitor, following single and re-peated administration in healthy adult subjects. Antimicrob. Agents Chemother. 51:4284-4289.
47. Saenz, D. T., N. Loewen, M. Peretz, T. Whitwam, R. Barraza, K. G. Howell, J. M. Holmes, M. Good, and E. M. Poeschla. 2004. Unintegrated lentivirus DNA persistence and accessibility to expression in nondividing cells: analysis with class I integrase mutants. J. Virol. 78:2906-2920.
48. Sedaghat, A. R., J. B. Dinoso, L. Shen, C. O. Wilke, and R. F. Siliciano. 2008. Decay dynamics of HIV-1 depend on the inhibited stages of the viral life cycle. Proc. Natl. Acad. Sci. USA 105:4832-4837.
49. Sharkey, M. E., I. Teo, T. Greenough, N. Sharova, K. Luzuriaga, J. L. Sullivan, R. P. Bucy, L. G. Kostrikis, A. Haase, C. Veryard, R. E. Davaro, S. H. Cheeseman, J. S. Daly, C. Bova, R. T. Ellison III, B. Mady, K. K. Lai, G. Moyle, M. Nelson, B. Gazzard, S. Shaunak, and M. Stevenson. 2000. Persistence of episomal HIV-1 infection intermediates in patients on highly active anti-retroviral therapy. Nat. Med. 6:76-81.
50. Shun, M. C., N. K. Raghavendra, N. Vandegraaff, J. E. Daigle, S. Hughes, P. Kellam, P. Cherepanov, and A. Engelman. 2007. LEDGF/p75 functions downstream from preintegration complex formation to effect gene-specific HIV-1 integration. Genes Dev. 21:1767-1778.
51. Stevenson, M., S. Haggerty, C. A. Lamonica, C. M. Meier, S. K. Welch, and A. J. Wasiak. 1990. Integration is not necessary for expression of human immunodeficiency virus type 1 protein products. J. Virol. 64:2421-2425.
52. Svarovskaia, E. S., R. Barr, X. Zhang, G. C. Pais, C. Marchand, Y. Pommier, T. R. Burke, Jr., and V. K. Pathak. 2004. Azido-containing diketo acid derivatives inhibit human immunodeficiency virus type 1 integrase in vivo and influence the frequency of deletions at two-long-terminal-repeat-circle junctions. J. Virol. 78:3210-3222.
53. Temin, H., E. Keshet, and S. Weller. 1980. Correlation of transient accumulation of linear unintegrated viral DNA and transient cell killing by avian leukosis and reticuloendotheliosis viruses. Cold Spring Harb. Symp. Quant. Biol. 44:773-778.
54. Vandegraaff, N., R. Kumar, H. Hocking, T. R. Burke, Jr., J. Mills, D. Rhodes, C. J. Burrell, and P. Li. 2001. Specific inhibition of human immunodeficiency virus type 1 (HIV-1) integration in cell culture: putative inhibitors of HIV-1 integrase. Antimicrob. Agents Chemother. 45:2510-2516.
55. Venzke, S., and O. T. Keppler. 2006. The role of macrophages in HIV infection and persistence. Exp. Rev. Clin. Immunol. 2:613-626.
56. Wain-Hobson, S., C. Renoux-Elbe, J. P. Vartanian, and A. Meyerhans. 2003. Network analysis of human and simian immunodeficiency virus sequence sets reveals massive recombination resulting in shorter pathways. J. Gen. Virol. 84:885-895.
57. Wiskerchen, M., and M. A. Muesing. 1995. Human immunodeficiency virus type 1 integrase: effects of mutations on viral ability to integrate, direct viral gene expression from unintegrated viral DNA templates, and sustain viral propagation in primary cells. J. Virol. 69:376-386.
58. Wong, J. K., C. C. Ignacio, F. Torriani, D. Havlir, N. J. Fitch, and D. D. Richman. 1997. In vivo compartmentalization of human immunodeficiency virus: evidence from the examination of pol sequences from autopsy tissues. J. Virol. 71:2059-2071.
59. Wu, Y., and J. W. Marsh. 2003. Early transcription from nonintegrated DNA in human immunodeficiency virus infection. J. Virol. 77:10376-10382.
60. Wu, Y., and J. W. Marsh. 2001. Selective transcription and modulation of resting T cell activity by preintegrated HIV DNA. Science 293:1503-1506.
61. Zhang, J., D. T. Scadden, and C. S. Crumpacker. 2007. Primitive hematopoietic cells resist HIV-1 infection via p21. J. Clin. Investig. 117:473-481.